Zanolimumab Explained

Zanolimumab is an investigational human monoclonal antibody and an immunosuppressive drug.[1] It was developed with the goal of treatment of rheumatoid arthritis, psoriasis, melanoma,[2] cutaneous and peripheral T-cell lymphoma.[3] Development of the drug was ultimately discontinued with termination of all trials.[4]

References

  1. Mestel DS, Beyer M, Möbs M, Steinhoff M, Sterry W, Assaf C . Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome . Expert Opinion on Biological Therapy . 8 . 12 . 1929–39 . December 2008 . 18990079 . 10.1517/14712590802528696 . 58115371 .
  2. Web site: TenX BioPharma . August 20, 2010 . dead . https://web.archive.org/web/20100411114420/http://www.tenxbiopharma.com/development.shtml . April 11, 2010 .
  3. http://www.ama-assn.org/ama1/pub/upload/mm/365/zanolimumab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab
  4. Web site: Status of clinical trials for Zanolimumab. 6 November 2011. 27 May 2013. https://web.archive.org/web/20130527120616/http://clinicaltrials.gov/search/intervention=Zanolimumab. live.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Zanolimumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.